UK Cancer Biomarkers Market, Industry Trends, Size, Competitive Analysis and Forecast 2019-2025

UK cancer biomarker market is expected to grow at a CAGR of around 11.7% during the forecast period. The major factor that is increasing the market is a high prevalence of cancer in the region, well-developed healthcare infrastructure and the presence of the major market players in the nation. Additionally, as the country has developed economy, per capita healthcare investment from government and public is higher than other developing nation and hence significant research can be observed in the near future.

Request a Free Sample of our Report on UK Cancer Biomarkers Market: https://www.omrglobal.com/request-sample/uk-cancer-biomarker-market

The healthcare expenditure of the UK is more than $25,000 million as compared to Germany and France. This is one of the major factors that tend to rise the UK cancer biomarker market. AS per OECD, the prevalence of cancer in the UK is approx. 225 per 100,000 people in 2011 which is estimated to reduce only to 214 per 100,000 people in 2017. The incidences of cancer patients in the UK have been very frequent previously.

The increasing integration of healthcare with technology is augmenting the UK cancer biomarker market. There are various procedures that are being uniquely available at UK treatment centers. For instance, the Clatter Bridge Cancer Centre is one of the first two hospitals in the UK to offer dose painting radiotherapy to patients. The technique is suitable for patients with a higher density of cancer cells, which have not spread from the prostate gland. This applies to 30- 50% of all prostate cancer cases. While an equal amount of radiation is delivered by the standard radiotherapy on the prostate, in dose painting radiotherapy, MRI scans or PET CT scan first identify areas of the prostate which is more affected.

Further, during the year 2016/2017 the Cancer Research UK supported the research based on cancer worth $490.22 million. On the lung cancer research $55.11 million was spent whereas an amount of $44.06 million was spent in the research of colon and rectal cancer. For, breast cancer $ 41.65 million was spent on the research. The funding in the research is expected to motivate the UK market of cancer biomarker. Thus, such contributions by the government organizations is expected to further drive the UK cancer biomarker market.

A Full Report of UK Cancer Biomarkers Market is Available at https://www.omrglobal.com/industry-reports/uk-cancer-biomarker-market

UK Cancer Biomarkers Cancer Biomarker Market Segmentation

By Biomarker Type
o Genetic Biomarker
o Protein Biomarker

By Cancer Type
o Lung Cancer
o Prostate Cancer
o Breast Cancer
o Colorectal Cancer
o Cervical Cancer
o Other

By Applications
o Drug Discovery and Development
o Diagnosis
o Risk Assessment
o Prognostics

By Profiling Technology
o Omics Technology
o Immunoassays
o Cytogenetics
o Bioinformatics

Company Profiles
o Abbott laboratories Inc.
o Astellas Pharma Inc.
o Becton, Dickson and Co.
o Bio-Rad Laboratories, Inc.
o Danaher Corp.
o F. Hoffmann-La Roche Ltd.
o Merck and Co., Inc.
o Novartis AG
o Pfizer Inc.
o QIAGEN GmbH
o Thermo Fisher Scientific Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-cancer-biomarker-market

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.